• The nurses from across Burjeel Holdings were surprised with brand-new Toyota RAV4 vehicles 

• Driving Force Award celebrates nursing excellence and acknowledges the dedication of working professionals 

Abu Dhabi, May 5, 2025 – In a heartfelt celebration and a unique gesture of gratitude, ten frontline healthcare professionals were honored with a life-changing surprise. In a special event organized by Burjeel Holdings, kickstarting the International Nurses Day celebrations, these healthcare heroes from across the Group’s hospitals and medical centers were presented with a brand-new Toyota RAV4, a gesture of gratitude that left recipients and onlookers deeply moved.  

The Driving Force Award, an initiative celebrating nursing excellence, acknowledged the compassion, perseverance, and emotional labor that define the nursing profession. With senior leadership, colleagues, and families present, the moment captured the spirit of appreciation for those who work quietly, tirelessly, and with heart. The car keys were handed over by Mr. John Sunil, Group CEO, and Mr. Safeer Ahamed, Group Co-CEO of Burjeel Holdings. In the runup to International Nurses Day, the Group will go on to honor 100 more exemplary nurses from across its hospitals and medical centers with cash prizes. 

“We often talk about excellence in numbers, metrics, and outcomes. But true nursing excellence lives in the quiet hands that comfort, the voices that reassure, and the hearts that keep hope alive. The Driving Force Award is our way of saying: we see you; we value you. And we’re deeply grateful,” said John Sunil, Group CEO of Burjeel Holdings. 

Surprises All Around 

For Mei Alegre, a Filipino Nurse Manager at Burjeel Hospital, Abu Dhabi, the moment was surreal. A nurse with nine years of service at Burjeel, she arrived believing she was simply participating in an International Nurses Day event. 

“I thought I was just coming to speak about my experience,” she said through tears. “Never in my life did I imagine this. I’ve always loved my job, but to be appreciated like this — it’s overwhelming.” 

Reflecting on her journey, she shared, “Even though I’ve transitioned into a managerial position, many of my former patients still recognize me. In those moments, I feel a deep sense of pride knowing that the care I provided made a lasting difference.” 

For Soher Mohammed Ahmed Ali, an Egyptian Nursing Educator at Medeor Hospital, Abu Dhabi, the recognition carried deep personal meaning. Having lost her father to cancer, she dedicated her life to supporting others. “I couldn’t help my father, but maybe I can help others through what I do,” she said, adding, “When patients or their families pray for me, when they say a quiet dua. That’s more than enough. That’s everything.” 

The recognition, she says, felt deeply personal. “Being a nurse is part of who I am. This award reminds me that our presence and our care truly matter.” 

Nabil Mohamed Ikbal, a registered nurse at Lifecare Hospital, Baniyas, described the moment as “unreal.” With four years in the system, the Indian nurse saw the moment as a meaningful symbol of validation.  

He recalled one of his proudest moments — leading the resuscitation of a patient who had been without pulse or breath for over 20 minutes. “We continued CPR for 50 minutes. Everyone thought there was no hope. But the patient came back. That’s the kind of team I have. That’s the kind of profession nursing is.” 

Recognizing the Quiet Heroes of Healthcare 

The other winners included Mohammed Hamid Taher from Jordan and Mark Darrel Manalo De La Cruz from the Philippines, and Ani M. Jose, Archanakumari Viswanatha Panicker, Priyanka Devi Kaleeswaran, Sibi Mathew, and Vishnuprasad Sasthamkovil from India. 

Senior leaders, family members, colleagues, and patients came together to celebrate stories that often go unnoticed. The evening was a tribute to those who go above and beyond, shift after shift. 

Winners were selected after months of assessments across Burjeel units. The unit-level committees reviewed the nurses’ performance, community service, and patient impact, before forwarding final nominations to a central jury. The outcome was kept completely confidential, making the final reveal a true surprise.  

The agreement establishes referral pathways for international patients, allowing for direct case management and clinician access. 

Abu Dhabi, UAE, 18 March 2024: Etihad Airways, the national airline of the UAE, has signed a Memorandum of Understanding (MoU) with Burjeel Holdings, a leading super-specialty healthcare provider in the MENA region, to advance Abu Dhabi’s standing as a global hub for medical tourism. The collaboration is a gateway to world-class healthcare for international patients and expands access to medical services for Etihad employees and their families. 

The MoU was signed by Dr. Muntaser Husein, Director of Health and Wellbeing at Etihad Airways, and Dr. Mohammad Qaddoura, COO, Abu Dhabi Emirate and Oman at Burjeel Holdings, in the presence of senior executives from both organizations. By combining Burjeel’s advanced medical expertise with Etihad’s international reach, the collaboration will support Abu Dhabi’s efforts to welcome more medical tourists and deliver high-quality healthcare solutions. The agreement also establishes referral pathways for international patients, allowing for direct case management and clinician access. 

Through this collaboration, Burjeel Holdings will ensure comprehensive healthcare coverage for Etihad’s workforce and their families by providing seamless access to its network of hospitals and medical centers across Abu Dhabi, Dubai, Sharjah, Al Ain, and Al Dhafra.  

“This collaboration will streamline medical services for international travelers seeking specialized treatment in Abu Dhabi The partnership with Burjeel Holdings allows us to provide our employees and their families with exceptional medical care, offering access to some of the most advanced healthcare services in the region,” said Dr. Muntaser Husein.  

As part of the agreement, Burjeel will introduce health awareness programs and wellness lectures to support employee well-being. Additionally, priority access to medical services will be provided, ensuring streamlined procedures and enhanced healthcare privileges for all Etihad employees. 

“Joining hands with Etihad Airways strengthens our commitment to positioning Abu Dhabi as a premier destination for medical tourism, offering seamless access to world-class healthcare for travelers and residents alike. By integrating Burjeel Holdings’ healthcare expertise with Etihad’s global network, we are creating a seamless system for medical access, high-quality treatment, and unparalleled patient experience. Our goal is to ensure that every traveler, employee, and family member can receive world-class medical care with ease and efficiency,” said Dr. Mohammad Qaddoura. 

Burjeel Holdings is a key destination for patients seeking highly specialized medical care including advanced oncology treatments, bone marrow transplantation, hematology, trauma, multi-organ transplants, women’s care, fetal medicine, fertility services, pediatrics, orthopedics, spine, and neuro care in the region. 

The agreement builds on Burjeel Holdings’ commitment to expanding healthcare accessibility in the UAE. Last year, the Group launched the 24/7 Burjeel Airport Clinic at Zayed International Airport, providing round-the-clock medical support to travelers, airport staff, and international patients in need of specialized care. 

Abu Dhabi, 26 February 2025: Guided by the Department of Health – Abu Dhabi (DoH), Burjeel Medical City (BMC) has administered Givosiran, an innovative treatment for a rare genetic disorder that leads to the buildup of toxic metabolites in the liver, for the first time in the UAE, marking a significant milestone for healthcare in the country.  

Muhammad, a 21-year-old Emirati diagnosed with Acute Intermittent Hepatic Porphyria (AIP), a rare condition that affects only five in one million people, was the first patient in the UAE to receive the Givosiran medication at BMC. AIP, caused by a defective enzyme, leads to the accumulation of toxic metabolites in the liver. These metabolites trigger symptoms such as neuropsychiatric disorders, and can result in life-threatening complications, including renal failure, paralysis, liver failure, and liver cancer. 

Dr Asma Al Mannaei, the Executive Director of the Health Life Science Sector at the Department of Health – Abu Dhabi (DoH), said: “Abu Dhabi is dedicated to delivering the highest quality of care and enhancing the health and well-being of our community. Integrating the latest health technology innovations reflects the commitment of all stakeholders to position Abu Dhabi as a leading global healthcare destination. 

“The Department’s Research and Innovation Centre’s multidisciplinary team thoroughly evaluated, coded and documented the medication with an identification code. This process enables healthcare facilities in the Emirate to efficiently provide the medication and ensures its inclusion in the health insurance network, streamlining access to the treatment. Administered as a monthly injection, this innovative treatment, utilises small interference RNA technology to effectively reduce the levels of toxic metabolites in the body.” 

Dr Niyas Khalid, Specialist – Internal Medicine at BMC, said: “Muhammad’s case represents a significant milestone in treating rare diseases in the UAE. Givosiran is now officially available on the list of approved drugs in the country, paving the way for more patients to access this treatment. This case demonstrates BMC’s prowess in rare diseases and complex care. Some genetic diseases can have very uncommon presentations. But with a high level of suspicion and expertise, it is possible to decode them. “ 

Muhammad’s mother said: “Our son battled a rare health condition for years. The debilitating attacks of  severe abdominal pain, constant fatigue, weight loss, and frequent hospitalisations were devastating. Meeting Dr Niyas Khalid at Burjeel Medical City (BMC) marked a turning point, his persistence and expertise led to the correct diagnosis. I am grateful to the Department of Health – Abu Dhabi (DoH) for facilitating the treatment for my son in record time. 

“After Muhammad’s first dose of Givosiran, we noticed a significant decrease in his attacks. We thank our wise leadership for their unwavering support in providing modern treatments and the medical team at BMC.” 

The medical team at BMC continues to monitor Muhammad’s progress, aiming for Givosiran to significantly improve his quality of life and prevent further complications. An ENVISION clinical study demonstrated a 74 per cent reduction in annualised attack rates, a 90 per cent reduction in ALA and PBG levels, and a significant improvement in patients’ quality of life. 

• Acquires 80% stake in Dubai-based Advanced Care Oncology Center  

• Announces plan to launch ACOC-branded radiation oncology centers across GCC 

Abu Dhabi, UAE, February 18, 2025: Burjeel Holdings PLC (“Burjeel” or “the Group”), a leading super-specialty healthcare provider in the MENA region, listed on the Abu Dhabi Securities Exchange (SYMBOL: BURJEEL; ISIN: AEE01119B224), has announced its plan to establish the leading radiation oncology network in the GCC, following its successful acquisition of an 80% stake in the Dubai-based Advanced Care Oncology Center (ACOC), renowned for its specialized expertise in radiation therapy, nuclear medicine, and chemotherapy services.This transformative initiative aims to redefine cancer care delivery in the region, leveraging ACOC’s expertise to build a network that ensures accessible and advanced oncology treatment. 

Oncology Global & GCC Landscape 

Globally, cancer cases are projected to increase significantly, driven by aging populations and lifestyle changes. According to the World Health Organization, annual global cancer diagnoses are expected to rise from 20 million in 2024 to over 30 million by 2040, highlighting the growing global burden of cancer. 

In the GCC, the oncology landscape presents both challenges and opportunities. Cancer cases in the region are anticipated to grow by approximately 50% over the next two decades, driven by similar demographic and lifestyle trends. However, the region faces a critical shortage of cancer care infrastructure to manage the growing cases, leading to substantial unmet demand for specialized oncology services. This highlights the immense potential for Burjeel Holdings to expand its oncology platform, ensuring timely and effective cancer treatments to meet regional healthcare needs. 

Additionally, the growing adoption of advanced oncology solutions, such as radiation therapy, robotic surgical oncology, and precision medicine, demonstrates a clear trend towards innovative and specialized care pathways in the GCC. 

Driving Cancer Care Leadership in the GCC 

The planned ACOC-branded network aims to strategically improve oncology access  in underserved markets across the GCC.  

• Enhance Accessibility: The stand-alone ACOC centers will serve as trusted hubs for radiation therapy, expanding patient access to specialized care in underserved regions across the UAE and the GCC. 

• Integrate Advanced Technology: Each center will be equipped with cutting-edge technologies, including state-of-the-art LINAC systems, AI-driven radiation planning, and precision imaging tools.  

• Streamline Referrals: By offering focused and dedicated radiation therapy services, ACOC-branded centers will establish a robust platform for referrals from a broad network of healthcare providers. 

• Support Burjeel Cancer Institute: The network will support Burjeel Cancer Institute (BCI), the Group’s hub for advanced cancer treatments. Patients requiring surgical oncology, immunotherapy, robotic surgery, and bone marrow transplants will benefit from a smooth and integrated transition to the Group’s comprehensive, cutting-edge care. 

• Foster Research & Innovation: Leveraging the Oracle Health EMR implementation for its diverse patient base, the network will drive medical research and data-driven innovations, further solidifying Burjeel’s leadership in preventive oncology and precision medicine. 

Further information, including details of the expansion plan, will be disclosed in due course. 

Burjeel Cancer Institute: Anchor of Burjeel’s Oncology Platform 

This acquisition is a strategic fit for the Group’s growing oncology platform, anchored by BCI,  one of the UAE’s largest cancer care networks. With facilities spanning Abu Dhabi, Al Ain, Al Dhafra, Sharjah, and Dubai, the Group delivers integrated and comprehensive oncology services. These include medical oncology, radiation therapy, robotic surgical oncology, bone marrow transplants, and palliative care. The integration of ACOC into Burjeel’s ecosystem will enhance synergy between stand-alone radiation oncology centers. This structure ensures a streamlined and efficient care pathway, where referrals to the Group are directed toward highly specialized treatments, complementing the network’s broader accessibility and outreach.    

Mr. John Sunil, Group CEO of Burjeel Holdings, said: “Our vision is to establish a comprehensive and advanced oncology network in the GCC, addressing unmet needs in specialized cancer care. By building on ACOC’s legacy of excellence, we will bring accessible, high-quality radiation oncology services closer to patients, significantly enhancing cancer care outcomes across the region. This network will not only support early intervention and treatment but will also connect seamlessly with the Burjeel Cancer Institute for advanced therapies.” 

ACOC Transaction Highlights 

• Value Transaction: Burjeel has acquired an 80% equity stake in ACOC for AED 92 million on a cash-free, debt-free basis, with an option to acquire the remaining stake. ACOC recorded revenue of AED 64 million in 2024. 

• Continuity of Leadership: ACOC’s Founder and CEO, Bashir Abou Reslan, retains a 10% stake and continues to lead the center’s operations, ensuring continuity and excellence in patient care. The remaining 10% continues to be held by Raphael Khlat Middle East FZCO, an existing shareholder. 

About Burjeel Holdings  

Founded in 2007, Burjeel Holdings is a leading super-specialty healthcare services provider in the UAE and Oman, and it operates a growing specialized healthcare segment in Saudi Arabia. The Group operates an integrated and multi-brand healthcare ecosystem across primary, secondary, tertiary, and quaternary medical care, ensuring complex care delivery to patients across all socioeconomic groups. Its network comprises 100 assets across the UAE, Oman, and Saudi Arabia, including 19 hospitals, 29 medical centers, 29 physiotherapy and wellness centers, 15 pharmacies, and other allied services. Burjeel Holdings’ brands include Burjeel, Medeor, LLH, Lifecare, PhysioTherabia and Tajmeel. 

About Advanced Care Oncology Center 

Established in 2017, ACOC is a trusted provider of integrated cancer care services in Dubai. The center is renowned for its specialized expertise in radiation therapy, nuclear medicine, and chemotherapy services. ACOC’s commitment to clinical excellence is underscored by its accreditations, including the Gold Accreditation from Accreditation Canada, awarded in August 2021. It is the only facility in the UAE to hold PET/CT EARL Accreditation from the European Association of Nuclear Medicine (EANM). Additionally, ACOC received the Certificate of Medical Prescription Audit from Bienzobas in Spain in October 2021, demonstrating compliance with European regulatory standards such as EMA guidelines and international protocols from NICE and NCCN. 

Contacts 

The Orthopedic Residency and Hematology-Oncology Fellowship programs will equip physicians with the expertise needed to meet global healthcare standards

Abu Dhabi, February 15, 2025: Burjeel Holdings, a leading super-specialty healthcare provider in the MENA region, has achieved a significant milestone in healthcare education by receiving accreditation from the National Institute for Health Specialties (NIHS), a prestigious accreditation program in the UAE. The two specialized medical training programs—Orthopedic Residency and Hematology-Oncology Fellowship—have secured this accreditation. The Hematology-Oncology Fellowship marks a milestone for Burjeel Holdings as the first healthcare provider in the UAE to achieve this recognition, while the accreditation for the Orthopedic Residency sets a precedent in Abu Dhabi’s private healthcare sector.

The accreditation was officially conferred by Dr. Mohammed Al Houqani, Secretary General of NIHS during a ceremony attended by Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, H.E. Dr. Rashed Alsuwaidi, the Acting Director General of Healthcare Regulatory at Department of Health – Abu Dhabi, Mr. John Sunil, Group CEO of Burjeel Holdings, and Mr. Safeer Ahamed, Group Co-CEO of Burjeel Holdings.

Dr. Mohammed Al Houqani praised Burjeel Holdings’ role in advancing medical education, highlighting its significant contributions to training the healthcare workforce and equipping them with the highest global standards. He emphasized the Group’s efforts in creating an ideal training environment based on best medical practices, which will strengthen the healthcare sector with specialized and qualified physicians capable of delivering high-quality medical services for healthcare challenges.

Speaking about this achievement, Dr. Tahani Al Qadiri, Group Director of Emiratization and Academics at Burjeel Holdings, said that this accreditation is a testament to Burjeel’s commitment to raising the next generation of specialized healthcare professionals in the region. “This milestone not only strengthens our position as a leader in private-sector medical education but also contributes significantly to Abu Dhabi’s healthcare ecosystem by nurturing highly skilled specialists,” she added.

These specialized programs will provide rigorous, hands-on training for medical residents and fellows, equipping them with the expertise required to meet global healthcare standards. The Orthopedic Residency Program will prepare aspiring trainees with comprehensive clinical experience, while the Hematology-Oncology Fellowship Program will cultivate highly specialized expertise in cancer care.

According to Prof. Humaid Al Shamsi, CEO of Burjeel Cancer Institute, the initiative will contribute to better patient outcomes. “By establishing the first accredited Hematology-Oncology Fellowship Program in the private sector in the country, we are creating a structured pathway for developing highly skilled oncologists who will play a crucial role in enhancing cancer care in the region,” he said.

Dr. Mohamed Muath ADI, Consultant Orthopedic Surgeon at Burjeel Medical City (BMC) and Program Director of the Orthopedic Residency Program, said that this milestone will enhance the quality of orthopedic education and training in the region, further elevating the standard of orthopedic care in the UAE.

This accreditation, aligning with the UAE’s strategic vision to advance the healthcare sector, reflects Burjeel’s commitment to advancing medical education, and positioning Abu Dhabi as a hub for world-class medical training.

The Group’s flagship BMC to provide a comprehensive training program, enhancing the expertise of healthcare professionals in Egypt and the region.

Dubai, UAE, January 30, 2025: In a significant step towards strengthening healthcare collaboration, the Ministry of Health, Egypt and Burjeel Holdings, a leading super-specialty healthcare services provider in the MENA region, have signed a Memorandum of Understanding (MoU) at Arab Health 2025. The agreement paves the way for a strategic partnership aimed at expanding access to advanced oncology care across Africa, with a particular focus on developing a comprehensive Bone Marrow Transplant (BMT) Program. This initiative will be spearheaded by Burjeel Medical City (BMC), the flagship facility of Burjeel Holdings, supported by Burjeel Cancer Institute, the largest integrated cancer care network in the UAE.

The agreement was signed by Dr. Maha Ibrahim, Head of the Secretariat of Specialized Medical Centers, Ministry of Health, Egypt, and Mr. John Sunil, Group CEO of Burjeel Holdings, in the presence of H.E. Khaled Abdel Ghaffar, Deputy Prime Minister and Minister of Health and Population of Egypt, Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, Mr. Omran Al Khoori, Member of the Board of Directors, Burjeel Holdings, and Mr. Safeer Ahamed, Group Co-CEO, Burjeel Holdings.

Focus on Bone Marrow Transplants

As part of the commitment to improving patient outcomes, the collaboration will develop a dedicated strategy to address and reduce the backlog of BMT patients in Egypt, ensuring timely access to life-saving procedures. Under this initiative, Burjeel Holdings will leverage its expertise from its highly successful BMT program at BMC to establish a world-class transplant unit in Egypt. The program will integrate proven protocols, advanced treatment methodologies, and multidisciplinary clinical approaches to enhance patient care and improve transplant success rates.

Comprehensive training for adult and pediatric BMT programs will be provided, empowering physicians, nurses, lab technicians, and supporting services in Egypt. The training will include hands-on experience in cutting-edge transplant techniques, post-transplant care, and multidisciplinary patient management, ensuring that local medical professionals are equipped with the latest advancements in BMT care.

Furthermore, the MoU paves the way for a research partnership between the Health Ministry and BMC, focusing on pioneering cancer treatments such as CAR-T cell therapy to advance Egypt’s capabilities in next-generation oncology solutions and innovative therapies.

Speaking on the occasion, H.E. Khaled Abdel Ghaffar stated, “This partnership with Burjeel Holdings underscores our commitment to enhancing healthcare accessibility and innovation in Egypt. By leveraging their expertise in oncology care, BMT program, and medical training, we aim to bring the highest standards of cancer treatment to our patients.”

Oncology Nursing Training, Technology Integration

In addition to BMT training, the partnership will extend specialized training to radiation oncology staff on advanced techniques, including stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) using the cutting-edge BrainLab system. To enhance diagnostic and precision medicine capabilities, staff will also receive training in molecular lab techniques, molecular pathology, and digital pathology, in collaboration with OncoHelix.

A one-year specialized oncology nursing training program will be launched, further strengthening the expertise of healthcare professionals in Egypt and the region. The initiative will also support the recruitment of oncology-trained nurses and facilitate authority accreditation, reinforcing long-term collaboration in cancer care.

Dr. Shamsheer Vayalil said, “We are honored to collaborate with the Ministry of Health, Egypt, in driving transformative changes in oncology care. Through strategic initiatives in training, research, and patient access, we look forward to making a meaningful impact in cancer treatment in Egypt.”

Additionally, a medical tourism framework will be established between the Ministry, designated agents, and BMC to enhance oncology care accessibility for patients across Africa. This initiative aligns with Egypt’s healthcare transformation goals, ensuring sustainable growth, stronger partnerships, and expanded access to specialized oncology care.

The agreement marks a significant milestone in Egypt’s healthcare advancement. By integrating expertise, cutting-edge technology, and world-class training programs, this collaboration between the Ministry of Health and Burjeel Holdings is set to redefine cancer care in the region.

Despite the gruelling treatments, Khaled refused to lose hope and drew strength from his faith and the unwavering support of friends, fellow survivors

Published: Thu 15 Feb 2025

A young UAE footballer’s life took an unexpected turn when persistent headaches, extreme sensitivity to light and sound, and constant nausea led to a shocking diagnosis. At just 26, Khaled (name changed) was diagnosed with a rare and aggressive brain tumour.

While working as an administrative employee, his true passion remained on the football field, where he played semi-professionally for Al Wahda and Baniyas Clubs in the UAE.

“I was at the start of my life, with so many dreams ahead of me. When I heard I had brain cancer, it felt like my world had stopped,” said Khaled. What followed was a gruelling battle involving multiple surgeries and years of radiation therapy as he fought anaplastic ependymoma with RELA fusion.

Advanced imaging revealed a large mass in his brain, requiring immediate surgery at Burjeel Hospital. He was then transferred to the Burjeel Cancer Institute (BCI) at Burjeel Medical City for specialized oncological care.

After a comprehensive pathology review, doctors recommended targeted radiation therapy. His initial treatment, completed in early 2021, showed promising results, with no immediate signs of disease progression. But by the end of the year, the aggressive tumour made a devastating comeback.

Race against time

New scans revealed five additional lesions in his brain, requiring a second surgery. Due to their locations and sizes, only three out of the five lesions could be removed. Doctors also found that the disease had spread aggressively, with multiple smaller lesions scattered throughout his brain.

After a detailed review by a multidisciplinary tumour board, a second round of radiotherapy was recommended, this time covering both the brain and spinal cord. However, just two sessions into the treatment, Khaled began experiencing worsening neurological symptoms.

A follow-up scan revealed that the two remaining lesions had grown significantly, necessitating a third brain surgery.

“My body was growing weaker by the day. I was used to moving and playing sports, but this was an entirely different kind of challenge,” he said.

Fighting against the odds

Despite the gruelling treatments, Khaled refused to lose hope. He drew strength from his faith and the unwavering support of friends, especially fellow cancer survivors.

One of his biggest inspirations was former UAE footballer Fahad Masoud, who also battled cancer. “I admired him as a player and followed his journey before and after his illness. Seeing how he kept going despite his challenges truly motivated me,” said Khaled.

By 2022, he had successfully completed his second round of radiotherapy.

New lease on life

“This case challenged us both clinically and emotionally. We had to prepare Khaled and his family for the worst, yet miracles do happen. His recovery is truly a blessing,” said Dr Ibrahim Abu Gheida, chief medical officer and clinical director of Radiation Oncology.

Radiation therapy played a crucial role in Khaled’s treatment. As one of the three main pillars of cancer care, alongside surgery and chemotherapy, it helped target recurring tumours while minimising damage to surrounding healthy tissue.

“Radiation oncology is a cornerstone in the fight against cancer. Khaled’s case was particularly challenging, but our multidisciplinary approach ensured he received the best possible care,” added Dr Abu Gheida.

Back on the field

Nearly five years after his diagnosis, Khaled regained his strength, resumed exercising, and even played football recreationally. “This journey taught me patience,” he said.

His message to others fighting similar battles is simple: “You are stronger than the disease.”

Maya, a breast cancer survivor, underwent Whipple procedure to treat periampullary cancer

February 15

Abu Dhabi: In a story of resilience and courage, a 59-year-old Emirati mother of five has triumphed over a second cancer diagnosis, this time with the aid of cutting-edge robotic surgery that removed several organs with unparalleled precision.

A ‘second cancer’ refers to a new type of cancer that develops after a patient has been treated for an initial, unrelated cancer.

In this case, Maya Muhammad Al-Hajri, a breast cancer survivor from Abu Dhabi, underwent a complex 12-hour Whipple procedure using robotic technology to remove her gallbladder, parts of her pancreas, stomach, and surrounding structures, successfully treating a rare and life-threatening periampullary cancer.

Her health ordeal began seven years ago when Maya was diagnosed with breast cancer, which was treated in 2019. Despite the emotional toll of that experience, she lived a determined life only to face a new challenge.

“I thought my nightmares were over, but they weren’t,” Maya, an administrative employee, recalled.

In July 2024, Maya developed jaundice because of a blocked biliary system, which led to the discovery of a tumour in the periampullary region – the area where the bile and pancreatic ducts meet.

Surgery lasted half a day

Doctors at Burjeel Medical City (BMC) recommended the Whipple procedure – a high-risk surgery to remove the gallbladder, bile duct, part of the pancreas, stomach, small intestine, and lymph nodes. Traditionally, this procedure requires a large abdominal incision and a multidisciplinary surgical team. However, at BMC, the surgery was performed using the da Vinci robotic system, a breakthrough in minimally invasive surgery introduced at the hospital in 2023.

Maya was unperturbed by the idea of robotic surgery, understanding its numerous benefits.

“I was aware of its great advantages compared to traditional surgery, such as a reduced recovery period, smaller incisions, and lower risk of complications and bleeding. This made us confident in trusting this modern technology,” she said.

Dr Ali Iyoob, the lead surgeon, performed the procedure, which lasted about 12 hours.

“The robotic system allowed for greater precision, enhanced visualisation of intricate anatomical structures, and a reduced risk of complications,” Dr Iyoob, consultant and head of gastrointestinal surgery, said.

“Despite challenges like multiple affected lymph nodes, an enlarged liver with abnormal blood supply, multi-regional dissections, and pancreatic head resection in a confined anatomical space, the surgery went smoothly and successfully,” he noted.

Following the removal of affected organs, the surgery involved the highly complex reconstruction of the digestive pathways for food and bilio-pancreatic juices.

“Robotic technology significantly reduced the risk of inadvertent damage to surrounding organs, minimised blood loss, and improved the overall reconstruction process,” Dr Iyoob said.

The robotic approach facilitated safer and more precise reconnections of the smaller bile and pancreatic ducts, reducing the likelihood of leaks that could complicate recovery.
“Thanks to the da Vinci system, the patient’s recovery was swift. The precision and efficiency of the robotic procedure were key in allowing her to return to her daily life sooner than expected,” Dr Iyoob underlined.

Currently, Maya is leading a happy and peaceful life and is grateful for the availability of advanced robotic treatments in the country.

“I thank my sister Rahma, my family, and the medical team for their full support as I overcame my health crisis. I have made a full recovery,” Maya said.

The newly launched Burjeel Orthopedic Institute brings together a comprehensive range of offerings catering to both adults and children.

Abu Dhabi, February 7, 2025 – His Highness Sheikh Nahyan bin Zayed Al Nahyan, Chairman of the Board of Trustees of the Zayed bin Sultan Al Nahyan Charitable and Humanitarian Foundation and Chairman of the Abu Dhabi Sports Council, has inaugurated the Burjeel Orthopedic Institute at Burjeel Medical City (BMC), the flagship quaternary care facility under Burjeel Holdings. The newly launched Burjeel Orthopedic Institute, led by a team of Emirati medical experts, brings together a comprehensive range of offerings catering to both adults and children, covering orthopedic medicine and surgery, sports medicine, rehabilitation, and bone cancer treatment.

His Highness Sheikh Nahyan bin Zayed Al Nahyan toured the Institute, where he was introduced to state-of-the-art medical technologies and world-class equipment. He also met with the Institute’s medical team and gained insight into the range of orthopedic services they offer.

The event was attended by Mr. Omran Al Khoori, Member of the Board of Directors, Burjeel Holdings; Mr. John Sunil, Group CEO of Burjeel Holdings; Dr. Mohammed Qaddoura, Chief Operating Officer, Abu Dhabi Emirate & Oman, Burjeel Holdings; and Dr. Mujtaba Ali Khan, CEO of BMC. Dr. Muhammed Ateeq Al-Falahi, Director General of Zayed bin Sultan Al Nahyan Charitable and Humanitarian Foundation; and Dr. Rashed Obaid Alsuwaidi, Executive Director of Healthcare Workforce Planning Sector at the Department of Health – Abu Dhabi, were also present at the event.

Burjeel Orthopedic Institute is the latest addition to Burjeel’s suite of specialized institutes—including the Burjeel Cancer Institute, Advanced Gynecology Institute, Kypros Nicolaides Fetal Medicine and Therapy Center, Burjeel ENT Head and Neck Institute, and the Trust Fertility Clinic.

BMC, which was recently accredited as a specialized center in orthopedic care in the Emirate by the Department of Health – Abu Dhabi, integrates specialized orthopedic and surgical care enhanced by artificial intelligence technologies. It offers services in joint repair and replacement, pelvic and upper shoulder procedures, spinal surgeries, sports medicine, limb lengthening, and pediatric orthopedic care. BMC also houses the Paley Middle East Clinic, specializing in the treatment of musculoskeletal deformities in children.

According to Dr. Mohamed Muath ADI, Head of Department and Consultant Orthopedic Surgeon, the Institute integrates diagnostics, treatment, and post-rehabilitation care in a seamless, patient-centered model.

“Burjeel Orthopedic Institute provides comprehensive musculoskeletal healthcare, covering everything from initial diagnosis to post-treatment rehabilitation. At BMC, we prioritize every detail of our patients’ journey—starting from initial examinations and leveraging the latest technologies to ensure a seamless and comprehensive treatment experience tailored to the entire family. Our expertise extends across sports medicine, spine care, pediatric orthopedics, and post-surgical rehabilitation, enabling patients to lead a pain-free life with improved quality of care,” he said.

At the Institute, Dr. Mohamed Muath ADI, leads a team of world-class experts including Dr. Sidahmed Abbas, Consultant Orthopedics, Trauma; Dr. Samih Tarabichi, Consultant Orthopedic Surgery; Dr. Jaber AlKhyeli, Consultant Orthopedics; Dr. Ahmad Baha Mousa, Consultant Orthopedic Surgeon; Dr. Maged Abu-Bakr Ahmed, Specialist Orthopedic Surgery; Dr. Mohamed Abdulgaffar Elbaz, Consultant Orthopedic Surgeon; and Dr. Naveed Pasha, Specialist, Orthopedic Surgeon.

Burjeel Orthopedic Institute is equipped with the latest robotic technologies for occupational and rehabilitation therapy, including underwater hydrotherapy and advanced patient clinics designed for optimal comfort. The Institute is also committed to continuous medical research, with its experts actively participating in global medical conferences and integrating the latest advancements in orthopedic medicine and surgery.

The new center reflects Burjeel’s ongoing commitment to expanding its services and meeting the growing healthcare needs of the community with integrated, world-class medical care

Al Ain, February 11, 2025 – Burjeel Cancer Institute (BCI), the largest cancer care network in the UAE, has expanded its reach by opening a new center at Burjeel Hospital Al Ain. This strategic expansion reinforces Burjeel Holdings’ commitment to providing world-class oncology services across the country, ensuring advanced cancer care is accessible to more patients.

The inauguration ceremony was attended by Mr. John Sunil, Group CEO of Burjeel Holdings, along with distinguished guests from the Al Ain Traffic Police, Abu Dhabi Agriculture and Food Safety Authority, and Al Ain Civil Defense.

BCI, the oncology arm of Burjeel Holdings, operates from its flagship facility, Burjeel Medical City in Abu Dhabi. At the forefront of oncology treatment and research, BCI brings cutting-edge therapies and a multidisciplinary approach to patient care. The new center at Burjeel Hospital Al Ain reflects its commitment to expanding services and meeting the community’s growing healthcare needs with integrated, world-class medical care.

The newly opened center in Al Ain offers a full spectrum of oncology services, including expert consultations, state-of-the-art diagnostic capabilities and specialized treatments such as chemotherapy, immunotherapy, and targeted therapies. The institute also provides comprehensive surgical oncology services, performed by a team of leading specialists utilizing the latest medical technologies to ensure precision and efficiency. To enhance patient comfort and privacy, the facility features dedicated chemotherapy suites, creating a supportive and personalized treatment environment. The seamless integration of these services ensures that patients receive a holistic care experience, from diagnosis through recovery.

Professor Humaid bin Harmal Al Shamsi, Consultant Oncologist and CEO of Burjeel Cancer Institute, emphasized the significance of this expansion.

“The opening of BCI in Al Ain reflects our commitment to expanding oncology services and making specialized cancer care more accessible across the UAE. Our goal is to bring high-quality, patient-centered treatment closer to those in need, ensuring that individuals in Al Ain have access to the latest advancements in cancer care without the need to travel far.”

“At BCI, we prioritize a seamless patient journey from diagnosis to treatment and recovery, with a multidisciplinary approach that enhances outcomes and quality of life. To further ease access to care, we welcome patients for consultations without requiring prior appointments, reinforcing our mission to provide an integrated and patient-first experience,” he said.

Dr. Aysha Almahri, CEO – Al Ain Region, Burjeel Holdings, highlighted the institute’s impact on cancer care in the region.

“At Burjeel, we recognize that the foundation of a thriving society lies in the health and well-being of its people. Cancer care is a top priority, and this expansion ensures that more patients have access to cutting-edge therapies, reducing the need for medical travel. With the establishment of BCI in Al Ain, we reaffirm our commitment to providing world-class oncology treatments to patients across the UAE.”

With the launch of the new center in Al Ain, Burjeel Holdings continues to redefine oncology care by offering patients state-of-the-art treatment options, further solidifying the UAE’s position as a regional leader in specialized cancer care.